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Background: This paper describes the development and validation of an electronic personal 
assessment questionnaire for vascular conditions (ePAQ-VAS) that captures symptomatology, quality 
of life and clinically relevant data to patients presenting to vascular services. 
   
Methods: A two-stage survey was conducted in patients attending a tertiary vascular department.  
Patients completed the ePAQ-VAS questionnaire remotely online or on site using an electronic tablet. 
In the first stage of the survey the responses were used to perform confirmatory factor analysis to 
assess the construct validity and remove redundant items. The internal reliability of disease-specific 
scales was investigated.  In the second stage of the survey, the acceptability, known-group validity, 
test-retest reliability and responsiveness of ePAQ-VAS was assessed.  
 
Results: In total, 721 patients completed ePAQ-VAS, the mean age was 63.5 years (15.7 SD); 64.9% 
were men (468); 76% of patients (553) completed the questionnaire in clinic and the remaining 
patients completed the questionnaire online. The results of the confirmatory factor analysis confirmed 
the conceptual model for ePAQ-VAS structure and eliminated six items. Internal reliability was 
acceptable for all the scales (Cronbach’s alpha >0.7). The test-retest reliability measured by the 
intraclass correlation coefficient ranged from 0.65-0.99. The results showed that the instrument is 
responsive over time with standardised response mean ranging from 0.69-1.60. 
 
Conclusions: ePAQ-VAS is a holistic data-collection process that is relevant to vascular service users 














Clinical outcomes in patients undergoing procedures for vascular diseases have been the focus for 
vascular services evaluation in the United Kingdom (1). These clinical outcomes, include technical 
measures such as patency and pressure indices or functional issues such as walking distance, may be 
a poor proxy for the effect of a condition on any patient. The use of these outcomes only reflects the 
impact of vascular disease and treatment on the small proportion of patients that develop adverse 
clinical outcomes (2), they do not measure the impact of vascular disease and treatment among 
many other patients, including those treated conservatively (2,3). 
In response to this problem, several condition-specific and generic patient-reported outcome 
measures (PROMs) have been developed or assessed for use in specific vascular conditions. These 
include condition-specific PROMs can capture aspects of disease important to patients and provide a 
picture about the impact of the disease on health-related quality of life (HRQoL) (4, 5), whereas, 
generic measures can be used to capture benefits across different conditions and treatments (5). 
PROMs can be used for diagnosis, monitoring, and measuring treatment effects, especially when 
integrated into an electronic patient record (EPR) platform (6). Increasingly, PROMs are being used 
to calculate quality adjusted life years for use in cost-effectiveness analysis of health and care 
interventions.  
The regular use of PROMs in clinical practice can guide treatment choice, shared decision making, 
and self-management. Evidence also suggests that clinicians can provide improved patient-centred 
care when PROMs are integrated into disease registries, where outcomes are tracked over time (6).  
However, the use of these measures to assess the impact of vascular conditions is limited to clinical 
studies and rarely used for patients’ assessment and service evaluation (7-11). This is in part because 
most vascular patients present with overlapping symptoms or mixed conditions, furthermore, 
logistically, it is difficult to use paper-based PROMs to monitor patients with chronic and recurrent 
vascular conditions (12-15).  
Hence, as part of the National Institute of Health Research (NIHR) programme considering the 
configuration and monitoring of vascular services, a new vascular PROM was developed. This new 
electronic tool followed the successful models in which electronic PROMs were used for patients’ 
diagnosis, assessment, and long term monitoring (16).  
The electronic patient assessment questionnaire for vascular patients (ePAQ-VAS) was developed in 
line with internationally recognised standards and guidelines (17-19).  It captures the impact of five 
main vascular conditions; abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD), 
carotid artery disease (CAD), varicose veins (VVs) and venous leg ulcers (VLU). The decisions to only 
include these conditions was based on systematic reviews and a clinicians’ consensus exercise (7-11, 
20). The advantages of this electronic tool are that it can be integrated into an EPR and facilitate 
focused consultations as patients can complete the questionnaire before the clinic appointment. 
Patients can complete the questionnaire on mobile phones or computers, and remote completion 
can facilitate virtual clinics. Furthermore, the electronic data generated by patients can help long 
term monitoring of disease, service evaluation, and linkage to other data. Lastly, this electronic tool 
incorporates skipping rules removing the need for patients to complete irrelevant sections.  





The conceptual framework for the ePAQ-VAS questionnaire was developed from three distinct 
sources to identify the key issues, symptoms and the impact of AAA, PAD, CAD, VLU and VV on patients 
with these conditions. First, systematic literature reviews of existing outcome measures and 
qualitative evidence were conducted (7-11, 21-24). Second, clinicians involved in the care of vascular 
patients were invited to list the key issues, symptoms and the impact of these conditions (20). Third, 
semi-structured interviews were conducted with five vascular patient groups PAD, AAA, CAD, VLU and 
VV. Users of vascular services attending the vascular department, Sheffield Vascular Institute (SVI) at 
the Sheffield Teaching Hospitals were recruited for this study purposive sampling techniques to ensure 
a range of participants at different age, sex and stages of treatment. Patients were asked about their 
symptoms, impact of the condition on their functioning and lifestyle. Framework analysis was used to 
study the qualitative data from the interviews and six overarching themes were identified for patients 
with PAD, AAA, CAD, VLU and VV. These were symptoms (including pain), impact on physical function, 
social impact, psychological impact, financial impact and lifestyle.  (25).  
The themes identified above were used by the ePAQ-VAS steering committee (SCR, GJ, PP, EL, AA) to 
generate items (questions) for the initial item pool (see supplementary material Appendix 1).  
The list of items was presented first to 13 clinicians involved in the care of vascular patients who were 
invited to score the relevance of items in the provisional version of ePAQ-VAS and suggest new items 
(20). Second, to ensure face validity, interviews were conducted with 19 patients, purposefully 
sampled from vascular populations previously described.  Inputs from clinicians and service users were 
used to revise the questionnaire by deleting 59 items, adding 5 items and rephrasing 12 items. 
The resulting ePAQ-VAS had 114 items and these were divided into sections, including a generic 
section asking about common vascular symptoms, relevant medical conditions, medications, clinically 
relevant questions (e.g. smoking, weight, diabetes) and screening questions to ensure only relevant 
questions are presented to the patients based on their specific vascular complaint. There were three 
disease specific sections including AAA, CAD and lower limbs sections. In these disease-specific 
sections there were eight scales with 55 items. The eight scales were CAD related anxiety, impact of 
CAD on activities of daily living (ADL), AAA related anxiety, impact of AAA on activities of ADL, PAD 
symptoms, VLU symptoms, VV symptoms and impact of lower limb vascular disease on ADL. For an 
overview of the development process see Figure 1.  
 
Insert Figure 1 here  
 
Item reduction and internal reliability  
Participants’ recruitment  
To reduce the burden of ePAQ-VAS, statistical analysis of the results of a survey was done to delete 
questions from ePAQ-VAS that were redundant. Consecutive patients attending outpatient clinics run 
by SVI between June 2017 and June 2018 were invited to complete the questionnaire online before 
their clinic appointment or onsite using electronic devices. Onsite, patients could complete questions 
and ask for technical help from researchers.  The five key vascular conditions identified (AAA, CAD, 
PAD, VLU and VV) were all represented in the sample. 
Statistical analyses 
Sample-size calculation was based on previous studies suggesting a required ratio between 4 and 10 
respondents per item to enable factor analysis and internal reliability calculations (26,27). Based on 
55 items within ePAQ-VAS contributing to eight scales, up to 550 patient completions were considered 
necessary.  
Item reduction  
One-factor confirmatory factor analysis (CFA) model for ordinal data (28) was fitted to each of the 
eight scales to test whether the empirical data supported the eight scales identified in the conceptual 
framework, The results of the analysis were also used to reduce the number of items. Appropriateness 
of the CFA model for each scale was assessed by examining the comparative fit index (CFI) and the 
root mean square error of approximation (RMSEA), where CFI >0.95 and RMSEA < 0.08 were regarded 
as appropriate fit (29). Furthermore, item factor loadings (>0.4); model residual correlations and 
modification indices were considered to examine local dependence within domains (29). For these 
three indices, their magnitude was evaluated in comparison to other items in the scale; when the 
modification indices (MI) were >100 and residual correlations (RC) >|.10| this was taken as the 
indicator of lack of fit and items were removed from the scale(29).   Redundant items were removed 
using the results from the CFA. MPlus version 8.2 (Muthen & Muthen, Los Angeles, California, USA) 
was used for the statistical analyses (30).  
 
Internal consistency 
To assess whether each scale within ePAQ-VAS was measuring what was intended cronbach alpha 
coefficient was calculated to measure internal consistency reliability. A Cronbach's alpha score of 
≥ 0·70 was considered acceptable, however scores exceeding 0·92 were taken to indicate that items 
in the scale may be redundant (18, 31).  
 
ePAQ-VAS acceptability, validity, reliability and responsiveness  
 
The results of relevant items from the above survey and an additional survey were used to validate 
the measure by examining acceptability, test-retest reliability, construct validity, and the 
responsiveness of the measure. 
 
Participants’ recruitment  
All consecutive patients invited to outpatient clinics run by the SVI from June 2018 to January 2019 
were asked to participate in this study.  For test -retest reliability, patients were asked to complete a 
second questionnaire three to seven days later, provided there was no change to their health status.  
Only patients with AAA, PAD, VLU and VV were included in this survey as CAD patients were only 
available prior to revascularisation procedures. To assess responsiveness, patients completed ePAQ-
VAS before, and six weeks after PAD and VV procedures. The second survey for test-retest reliability 
and responsiveness was completed over the telephone by one of the researchers.  
 
Statistical analyses  
Acceptability  
Acceptability of ePAQ-VAS was measured by examining the completeness of the data. Good level of 
acceptability is confirmed if 80-95% of the data are completed by the patients (31). Additionally, the 
mean and median of time taken to complete this instrument online or in clinic was calculated.  
 
Scoring  
A summative score for each the eight scales in ePAQ-VAS was calculated and standardised to a 0-100 
scale, where 0 indicates the best, and 100 the worst, outcome.  Skipped items were allocated a score 
of zero, as the questionnaire allows skipping of sections and individual questions that are not of 
relevance.   
 
Test-retest reliability   
Intra-class correlation coefficients (ICCs) were used to assess test-retest reliability. ICC exceeding 0.7 
are generally regarded as reliability for population-based research and ICCs exceeding 0.9 are 
considered to indicate reliability for use clinically with individuals (32).  
 
Known-group validity  
Known group validity was examined using hypothesis testing to examine whether the scales correlate 
well with expected clinical group differences.  Correlations are considered low if r < 0.3, moderate if r 
lies between 0.30 and 0.49 and high if r < 0.5(15). Hypotheses were stated a priori, including the 
postulated direction (17, 33). The clinical hypotheses proposed that the CAD anxiety and ADL scale 
scores would be higher (worse) for patients with stroke compared to those presenting with TIA. The 
AAA scale scare would be higher with patients with larger aneurysms and patients with ulceration or 
rest pain and PAD would have worse score than PAD patients with claudication.   For the list of these 
hypotheses for each condition,  see supplementary Appendix 2.  
Responsiveness 
Responsiveness was measured using standardised effect size, calculated as change of score between 
post-operative patient score and pre-operative score divided by standard deviation at baseline.  An 
effect size of 0.30 – 0.50 is regarded as ‘small’, 0.50 – 0.80 as ‘moderate’, 0.80 and above as ‘large’ 
(33).  Standardised response mean was also calculated as the mean difference between baseline and 
post-intervention divided by the standard deviation of the change, and classified using the same 




The response rate for patients invited to complete the questionnaire online prior to attending their 
clinic appointment was 24.2%.  In total 721 patients completed ePAQ-VAS, their mean age was 63.5 
(15.7 SD). 64.9% were men (468); 76% of patients (553) completed the questionnaire in a clinical 
environment (clinic or ward) and the remaining patients completed the questionnaire online. The 
mean time to complete ePAQ-VAS in the clinic was 12:51 minutes (Median, 09:14 minutes) and online 
prior to the clinic appointment was 36:51 minutes (Median 30:44 minutes), the difference in 
completion time is likely due to availability of help from researchers in clinics to complete ePAQ-VAS.  
ePAQ-VAS showed good acceptability with 350 item responses missing from 56,238 (0.62%).  The final 
scores were calculated for each scale and presented in Table 1.  
 
 
Insert table 1 here 
 
Item reduction  
 
The eight scales within the condition-specific sections of ePAQ-VAS were identified through qualitative 
evidence from patients and clinicians.   The responses of patients from the first survey were used in 
the CFA models to examine whether this structure was supported empirically. In the CAD section two 
scales were modelled and all items within the “CAD related anxiety” supported the latent factor.  
However, two items were dropped from “Impact of CAD on ADL” domain. The first was a generic item 
about the impact of CAD diagnosis on enjoyment of life, this item had high MI and RC with other items 
in the same scale. The other item deleted from this scale asked about impact on mood and this had 
low factor loading. In the AAA section, only one item asking about the impact of AAA on enjoyment of 
life was deleted, this item had high MI & RC with items in the same scale. A similar item asking about 
impact of lower limb symptoms on enjoyment of life was also dropped because high MI and RC with 
other items within the same scale. In the lower limb section two further items were dropped from the 
final version of ePAQ and these were asking about “cold feet” and VLU symptom, both items had low 
factor loading. For further details about the CFA models results, factor loading and other parameters 
please see supplementary material Appendix 3.  
A demonstration version of the final version of ePAQ can be viewed at: http://demo-
questionnaire.epaq.co.uk/home/project?id=aaa_1.0&page=1 
   
Internal reliability 
 
After dropping six items based on the results from the CFA, the internal consistency of each scale was 
examined, and all scales had a Cronbach’s alpha coefficient ≥ 0·70 and none exceeded 0·92. For further 





For the test-retest survey 150 patients (60 with PAD, 39 with VLU and 51 with VV), completed the 
relevant sections of a second questionnaire after 3-7 days.    Test-retest results were calculated for 
the symptom scale and impact of the lower limb vascular disease on ADL for patients with PAD, VLU 
and VV separately. The ICC ranged from 0.65 for VV symptoms to 0.98 for the PAD and Lower Limb 
ADL symptoms and 0.99 for the VLU symptoms as shown in supplementary material appendix 3, table 
5.    
 
 
Known-group validity  
 
The correlation between size of AAA and AAA related anxiety score was significant. There was a 
significant correlation between rest pain and PAD symptoms and impact of PAD on ADL. Presence of 
ulcer had a statistically significant correlation with the score on PAD ADL.   
Ulcer recurrence had a significant correlation with VLU symptom scale score. The presence of VV in 
both legs had a significant correlation with VV symptoms only and the presence of VV in both legs did 
not have strong correlations with scores of VV ADL. Correlations between the proposed clinical 
hypotheses and CAD ADL and CAD anxiety scores were low ranging from -0.089 to 0.094. This could 
be due to small sample size (n = 50 ) in the CAD group.  
The results of known group validity were mixed, with some being in line with proposed clinical 
hypotheses, for instance the larger the size of AAA the greater the anxiety caused by the condition 
and the presence of rest pain or ulcer significantly impact the score of PAD scales. However, some 
clinical hypotheses, particularly in CAD scale scores were not in line with what was proposed (see table 
2).  




In total 92 patients completed the responsiveness survey, of these, 55 patients had VV procedures 
and 37 lower limb revascularization procedures for PAD. These patients completed the ePAQ-VAS pre-
operatively and once more at least six weeks following their operation. All patients included in the 
analysis had successful outcomes from their procedure.  The effect size and standardised response 
mean were measured for all the relevant scales of ePAQ-VAS to examine whether ePAQ-VAS can pick 
up the difference in health status following successful interventions. As shown in table 3, the effect 
size was moderate for PAD symptoms and large for the remaining scales. The results for the 
standardised response means were all moderate apart from VV being large.  
 




Systematic reviews of condition specific vascular PROMs identified a lack of adequately validated 
tools for most vascular conditions (7-11).  The use of validated PROMs is limited and the data 
generated are rarely used in clinical decision making or monitoring of patients (9). The ePAQ-VAS is a 
tool that covers the five main vascular conditions of AAA, PAD, CAD, VVs and VLU. It has been 
developed in line with the FDA, the consensus-based standards for the selection of health 
measurement instruments (COSMIN) and other international guidelines (17-19). The items in this 
multi-sectional tool were developed based on the views of vascular patients experiencing the 
conditions and clinicians treating them. ePAQ-VAS was evaluated for its acceptability, reliability, 
validity and responsiveness in a large study involving 721 patients. The results of this study show 
that it has robust content and face validity and good acceptability, internal consistency, and 
responsiveness. Many of the scales within the ePAQ-VAS exhibit good test-retest reliability and 
known group validity.  
 
The main advantages of ePAQ-VAS are that it is a single instrument covering most patients treated 
by vascular services. This is particularly important for patients presenting with mixed symptoms or 
multiple conditions, therefore facilitating a focused, as well as holistic, approach to treat the causes 
of their symptoms. The electronic format of this tool makes it easier to monitor patients over time, 
especially those with chronic conditions and those treated with lifestyle modification or 
conservatively.  The questionnaire can be completed before the clinic or at the clinic before meeting 
the clinician and can help shared decision making and enable focused consultations. The data 
collected cover clinical and quality of life information and can be added to the patient electronic 
record. This can help assess the service over time if adopted locally and nationally. Evidence 
suggests that when electronic tools like ePAQ-VAS are included in disease registries they can 
facilitate patient centred care (6).  Another strength of ePAQ-VAS is that it generates detailed 
descriptions of the quality of life for people with different vascular conditions.  EQ-5D is a generic 
outcome measure with five dimensions (mobility, self-care, usual activity, pain, anxiety and 
depression) that can be used to generate quality adjusted life years, a composite measure of length 
and quality of life, that is recommended for use in economic evaluation (34). Therefore, if EQ-5D is 
used alongside ePAQ-VAS, utility values can be generated for the different vascular health states, 
which in turn can be used in economic evaluation in research settings and service evaluation in 
clinical settings. The disease specific data and utility values may also be used in the future to 
consider the relationship between such generic measures and the more detailed symptomatic and 
disease-specific description of vascular conditions provided by ePAQ-VAS. 
  
There are several limitations of this study, the  survey for validating this tool was conducted in a 
single centre. The patients completing the questionnaire were aware that they are completing it for 
research purposes only and that the results would not be used in their clinical consultation or 
management. This can be one of the reasons for the low completion rate of ePAQ-VAS prior to the 
clinic appointments. Previous experience with electronic ePAQ questionnaire used in other disease 
areas  suggest that patients are more likely to complete outcome measures before their clinic 
appointment when it is in routine clinical use and assist in their management (6, 35). Future studies 
are warranted to examine response rates and the discrepancy between response rates online before 
the clinic and at the clinic before meeting the clinicians.    Furthermore, the online nature of the 
questionnaire meant that younger patients or those with family support were more likely to 
complete ePAQ-VAS when compared to older patients and those less familiar with online 
technology.  
There was a discrepancy in the completion times for patients completing the questionnaire online 
before the clinic appointment and those completing it in the clinic before their appointment with 
the clinicians. This could be because patients completing online were unsupervised & unsupported, 
completion times may have been affected by variables such as Internet connection speeds as well as 
interruptions or distractions, which were not measured. The presence of researchers in the clinics 
could have introduced bias to the results of completion time and reduced this for those patients 
completing the questionnaire there. 
The sample size for some of the statistical analyses was small particularly for patients presenting 
with CAD and AAA. This was due to resource limitations of the research team and patient availability 
when compared to other disease groups such as PAD and VLU. The access to certain patient groups, 
especially for post-operative patients was limited. Fourth, the follow up data for test-retest and 
responsiveness were collected on the phone with the answers recorded by an interviewer. The 
presence of an interviewer could have introduced bias to the results and reduced completion time. 
Further studies can explore ways to improve data collection for follow-up data. Another area of 
validation of this instrument is the predictive validity and this can important for examining the ability 
of the questionnaire to monitor the impact of chronic vascular conditions on quality of life and the 
symptom change over time.  
 
This research has resulted in the development of a new electronic instrument, the ePAQ-VAS, for the 
collection of patient-reported outcome data that captures symptomatology, quality of life and other 
clinically relevant data such as experience with NHS services and co-morbidities, experienced by 
most patients presenting to vascular services.  Such data may contribute to electronic patient 
records and be invaluable in the management of individual patients and collection of aggregate data 
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